Junshengtai Pharmaceutical-B (02511): HTD1801 randomized controlled clinical study was positively evaluated

Zhitong Financial App News, Junshengtai Pharmaceutical-B (02511) issued an announcement. Recently, following the publication of the results of the Phase III clinical study (SYMPHONY-2) of the company's core product HTD1801 combined with metformin in the treatment of type 2 diabetes, “NEJM Evidence”, the clinical evidence sub-journal “NEJM Evidence” in the internationally renowned medical journal “New England Journal of Medicine” (NEJM), further published “NEJM Evidence” entitled “Berberine-Oxyoxycholate — Editorial (Editorial) on Combining Traditional Chinese Medicine to Our World. The editorial positively evaluated the rigorous design of the HTD1801 randomized controlled clinical study and continued accumulation of clinical evidence, and pointed out that the HTD1801 study provided a reference for promoting innovative drugs derived from the wisdom of traditional Chinese medicine to the world through high-quality clinical research. The publication of the above research results and editorials further shows that the clinical results of HTD1801 have received widespread attention and recognition from the international academic community.

Currently, the company is actively promoting the marketing and commercialization of HTD1801, and is in discussions with several potential partners on potential licensing and commercialization cooperation for the first marketing indication of HTD1801 in China. Under the potential cooperation, potential down payment, potential sales milestone payment, potential sales milestone payment, and sales commission may be paid to the Company. The Company will issue further announcements in due course as it progresses.

HTD1801 is a world-first novel molecular entity designed to address unmet clinical needs in cardiovascular and renal metabolic diseases (CKM). As a single molecule, HTD1801 is an oral anti-inflammatory and metabolic modulator (AIMM) with a unique dual mechanism. It exerts its biological activity by activating AMPK and inhibiting NLRP3 inflammasome; this complementary and collaborative dual mechanism can effectively solve metabolic problems. Numerous global clinical results confirm that HTD1801 can bring comprehensive benefits to patients, including improving insulin sensitivity, blood sugar control, blood lipid reduction, kidney protection, weight loss, liver benefits, and anti-inflammatory effects. Based on this, HTD1801 has the potential to become a basic therapeutic drug in the CKM field.